Friday, 27 Mar 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
10 Feb 2020 Social New Am Gastroenterology Assn Guidelines on Rx of Ulcerative colitis list infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib for moderate to severe UC. Rec against TOFA until failing a TNFi; against using MTX.
06 Feb 2020 Social QD Clinic - Part 4 of my discussion of 2020 EULAR recommendations for RA treatment - this one addresses Adding Biologics or JAK inhibitors. Watch on Youtube or Listen to the podcast
27 Jan 2020 ACR Video QD Clinic - When Would You Use Anakinra?
22 Jan 2020 News QD Clinic - Hepatitis B and Biologics
21 Jan 2020 News Biosimilars for Rheum Disease: Failure to Launch
17 Jan 2020 Social Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)]
02 Jan 2020 News Best of 2019 - Is Methotrexate Necessary with Tofacitinib?
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates.
31 Dec 2019 News Best of 2019 - Ups and Downs with Abatacept
30 Dec 2019 News Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?
26 Dec 2019 News Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots
25 Dec 2019 News Best of 2019 - Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis
23 Dec 2019 News Gilead Submits Filgotinib NDA to the FDA
16 Dec 2019 Social FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers.
11 Dec 2019 Social Biosimilar Tote-Board in Rheumatology: 4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola 5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada 2 Etanercept biosimilars - Erelzi, Enticovo 2 Rituximab biosimilars - Truxima, Ruxience
11 Dec 2019 Social FDA has approved Amgen’s infliximab biosimilar, Avsola (infliximab-axxq),for use in Crohns, UC, RA, AS, PsA and psoriasis, based on a 566 pt trial in RA. This is the 4th infliximab biosimilar in the US, joining Inflectra, Renflexis, and Ixifi.
10 Dec 2019 News Variations in First Biologic Use in Rheumatoid Arthritis
10 Dec 2019 Social BEST JOURNAL TITLE OF THE WK - "The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis."
28 Nov 2019 Social RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ…
26 Nov 2019 Social The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA).